Several independent datasets indicated that IGF2BP2 was expressed at high levels in OSCC tissues and that high expression predicts a worse prognosis than low expression, consistent with studies on acute myelocytic leukemia (27), hepatocellular carcinoma (11), and pancreatic cancer (28). This evidence concerns the gene IGF2BP2 and hepatocellular carcinoma.